Table 4. Knowledge of HPV-associated OPC patient characteristics and prognosis among 207 GPs in the Netherlands (2020).
| Total, n (%) | Sex, n (%) | Years after graduation as GP, n (%) | Self-rated knowledge of OPC, n (%) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | Male | P value | <2a | 2–5 | 5–10 | 10–20 | >20 | P value | Poor | Sufficient | Good | P value | |||
| OPC patients with HPV- associated tumours are more often: | Male | 74 (35.7%) | 38 (35.5%) | 36 (36.0%) | 0.415 | 6 (37.5%) | 4 (22.2%) | 17 (43.6%) | 21 (35.6%) | 26 (34.7%) | 0.424 | 16 (32.7%) | 51 (34.5%) | 7 (70.0%) | 0.003b |
| Female | 35 (16.9%) | 14 (13.1) | 21 (21.0%) | 4 (25.0%) | 4 (22.2%) | 5 (12.8%) | 11 (18.6%) | 11 (14.7%) | 3 (6.1%) | 31 (20.9%) | 1 (10.0%) | ||||
| Equal | 27 (13.0%) | 16 (15.0%) | 11 (11.0%) | 1 (6.3%) | 1 (5.6%) | 8 (20.5%) | 10 (16.9%) | 7 (9.3%) | 4 (8.2%) | 23 (15.5%) | 0 (0.0%) | ||||
| Don’t know | 71 (34.3%) | 39 (36.4) | 32 (32.0%) | 5 (31.3%) | 9 (50.0%) | 9 (23.1%) | 17 (28.8%) | 31 (41.3%) | 26 (53.1%) | 43 (29.1%) | 2 (20.0%) | ||||
| Total | 207 (100%) | 107 (100%) | 100 (100%) | 16 (100%) | 18 (100%) | 39 (100%) | 59 (100%) | 75 (100%) | 49 (100%) | 148 (100%) | 10 (100%) | ||||
| OPC patients with HPV- associated tumours are more often: | Age <60 years | 111 (53.6%) | 54 (50.5%) | 57 (57.0%) | 0.325 | 9 (56.3%) | 10 (55.6%) | 24 (61.5%) | 30 (50.8%) | 38 (50.7%) | 0.871 | 23 (46.9%) | 86 (58.1%) | 2 (20.0%) | 0.018b |
| Age >60 years | 42 (20.3%) | 26 (24.3%) | 16 (16.0%) | 4 (25.0%) | 4 (22.2%) | 8 (20.5%) | 13 (22.0%) | 13 (17.3%) | 8 (16.3%) | 28 (18.9%) | 6 (60.0%) | ||||
| Don’t know | 54 (26.1%) | 27 (25.2%) | 27 (27.0%) | 3 (18.8%) | 4 (22.2%) | 7 (17.9%) | 16 (27.1%) | 24 (32.0%) | 18 (36.7%) | 34 (23.0%) | 2 (20.0%) | ||||
| Total | 207 (100%) | 107 (100%) | 100 (100%) | 16 (100%) | 18 (100%) | 39 (100%) | 59 (100%) | 75 (100%) | 49 (100%) | 148 (100%) | 10 (100%) | ||||
| The prognosis of patients with HPV-positive OPC is generally ... compared with HPV-negative OPC | Better | 36 (17.4%) | 18 (16.8%) | 18 (18.0%) | 0.292 | 6 (37.5%) | 3 (16.7%) | 6 (15.4%) | 14 (23.7%) | 7 (9.3%) | 0.011b | 9 (18.4%) | 27 (18.2%) | 0 (0.0%) | 0.157 |
| Worse | 43 (20.8%) | 17 (15.9%) | 26 (26.0%) | 2 (12.5%) | 4 (22.2%) | 3 (7.7%) | 16 (27.1%) | 18 (24%) | 6 (12.2%) | 35 (23.6%) | 2 (20.0%) | ||||
| Equal | 10 (4.8%) | 6 (5.6%) | 4 (4.0%) | 0 (0.0%) | 2 (11.1%) | 0 (0.0%) | 2 (3.4%) | 6 (8.0%) | 1 (2.0%) | 8 (5.4%) | 1 (10.0%) | ||||
| Don’t know | 118 (57.0%) | 66 (61.7) | 52 (52.0%) | 8 (50.0%) | 9 (50.0%) | 30 (76.9%) | 27 (45.8%) | 44 (58.7%) | 33 (67.3%) | 78 (52.7%) | 7 (70.0%) | ||||
| Total | 207 (100%) | 107 (100%) | 100 (100%) | 16 (100%) | 18 (100%) | 39 (100%) | 59 (100%) | 75 (100%) | 49 (100%) | 148 (100%) | 10 (100%) | ||||
aAlso includes GPs still in training.bNo statistically significant trend observed with the extended Mantel-Haenszel test. P values were calculated with χ2 tests or likelihood ratio tests. HPV = human papillomavirus. OPC = oropharyngeal cancer.